Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando
Insight Molecular Diagnostics Inc. (IMDX)
Company Research
Source: GlobeNewswire
IMDX to host symposium on Wednesday, September 24th to discuss GraftAssureIQ™ at International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) annual meetingPresenting on GraftAssureIQ at symposium on Thursday, October 9th at the American Society of Histocompatibility and Immunogenetics (ASHI) annual meeting NASHVILLE, Tenn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced attendance at two key industry conferences where it will discuss its GraftAssure™ technology, including its clinical kitted test under development. At the 23rd IATDMCT annual meeting, which is being held September 21st to 24th in Singapore, iMDx will host a symposium to discuss the growing clinical applications of transplant rejection testing into longitudinal surveillance and therapeutic response monitoring, and the benefits of in-house testing. The symposium will highlight how GraftAssure, which is iMDx’s flagshi
Show less
Read more
Impact Snapshot
Event Time:
IMDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMDX alerts
High impacting Insight Molecular Diagnostics Inc. news events
Weekly update
A roundup of the hottest topics
IMDX
News
- Oncocyte (NASDAQ:IMDX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Oncocyte (NASDAQ:IMDX) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Oncocyte (NASDAQ:IMDX) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (d-)" rating on the stock.MarketBeat
- Oncocyte (NASDAQ:IMDX) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IMDX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> tMarketBeat
- Insight Molecular Diagnostics: GraftAssureDX FDA Submission Warrants Hold Rating [Seeking Alpha]Seeking Alpha
IMDX
Sec Filings
- 11/10/25 - Form 10-Q
- 11/10/25 - Form 8-K
- 11/4/25 - Form 4
- IMDX's page on the SEC website